IHS Chemical Week

Regions :: North Asia :: Taiwan

ScinoPharm and Foresee Pharmaceuticals to form drug development JV

12:48 PM MST | February 4, 2013 | Vincent Valk

ScinoPharm (Tainan, Taiwan) and Foresee Pharmaceuticals (Newark, DE) have signed a joint venture agreement under which they will develop injectable peptide drugs, starting with a Leuprolide oncological drug, the companies say. The jv involves a $3.6-million investment from ScinoPharm, and will develop a treatment for prostate cancer. Other details of the jv agreement have not been disclosed.   The new drug will be in the Phase III clinical trial in the United States by late 2013, the companies say. If the drug is approved by US authorities, it will be...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa